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Background: Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA), an observational, non-interventional, 24-week
post-marketing surveillance study in Japanese patients with type 2 diabetes (T2DM) having uncontrolled glycemic
control, demonstrated that basal supported oral therapy (BOT) with insulin glargine was an effective and safe
treatment in real-life clinical practice. We performed subgroup analysis to identify incidence and predictors
associated with risk of hypoglycemia.
Methods: Among 4219 patients with T2DM, 3732 patients were insulin-naïve and 487 patients were insulin
non-naïve who switched from other insulin to insulin glargine. All hypoglycemic episodes were counted by
physicians’ documentation based on patients’ reports. Relationships between baseline patient characteristics and
glargine-related hypoglycemic episodes were examined by univariate and multivariate analysis.
Results: Among 4219 patients, 44 (1.0%) patients experienced hypoglycemic episodes (41 insulin-naïve patients;
3 insulin non-naïve patients), with a rate of incidence 0.035 episodes/patient-years. Majority of patients with
hypoglycemia (37 of 44) had just one hypoglycemic episode during study period. Among insulin-naïve patients,
incidence of hypoglycemia differed significantly depending on age, diabetic complications, estimated glomerular
filtration rate (eGFR), and postprandial plasma glucose (P <0.05). In a multivariate adjusted model, poor renal
function (eGFR <60 mL/min/1.73 m2) was a statistically significant risk factor (P < 0.05).
Conclusion: Our results suggest that BOT using insulin glargine is an option of insulin therapy with 1% risk of
hypoglycemia in patients with T2DM with inadequate glycemic control. Patients with low renal function might
need a careful follow-up.
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High prevalence of type 2 diabetes mellitus (T2DM) in
Japan is associated with a significant economic burden,
which increases with increasing number of diabetic com-
plications [1]. Intensive glycemic control by multiple in-
sulin therapy has shown to delay onset and progression
of diabetic complications in Japanese patients with
T2DM [2]. However, intensive glucose-lowering treat-
ments used to achieve and maintain strict glycemic con-
trol are associated with increased risk of hypoglycemia
[3-6]. Hypoglycemia impacts morbidity, mortality and
quality of life of these patients [4,7-9], and also leads to
higher medical expenditure [10]. Thus, it can pose a hin-
drance in the management of T2DM and can be major
barrier in initiating and intensifying insulin treatment.
One way to ensure effective diabetes management is by
opting for therapies proven to be associated with low rate
of hypoglycemia. Previous data demonstrate that basal
long-acting insulin analogue, insulin glargine, results in a
reduced risk of nocturnal and severe hypoglycemic events
compared with conventional insulin therapies [11]. Basal
supported oral therapy (BOT) using insulin glargine is
known to be more simple, safe and effective, as compared
to neutral protamine Hagedorn (NPH) [12-15], insulin
lispro [16] and premixed insulin [17,18]. Earlier studies
in Japan also demonstrated that BOT with insulin glargine
was effective, without causing serious hypoglycemia
[19,20]. Another way to prevent or limit the incidence of
hypoglycemia is to understand the underlying contrib-
uting factors. Earlier studies demonstrated that factors
like old age, long disease duration, poor renal func-
tion, peripheral neuropathy, low body mass index
(BMI), ≥2glucose-lowering drugs, long duration of insulin
treatment, etc. are significant independent predictors
of hypoglycemia [3,21,22].
The Add-on Lantus® to Oral Hypoglycemic Agents
(ALOHA) study analyzed a large cohort of Japanese
T2DM patients with inadequate glycemic control and
demonstrated that BOT with insulin glargine was safe
and effective [23]. It demonstrated that diabetic retinop-
athy, medical history, history of allergy and adverse
events (AEs), and concomitant use of insulin resistance
reducing agents and drugs other than OADs, were con-
tributing factors to the occurrence of AEs. The ALOHA
database yielded further sub-analysis on various aspects
including dosing of insulin glargine and baseline predict-
ive factors for achieving glycemic control that have been
published [24-26].
To the best of our knowledge, there is no evidence on
incidence and predictors of hypoglycemia in Japanese
patients with T2DM. To address this need, we con-
ducted a sub-analysis of the data from the ALOHA
study to assess incidence of hypoglycemia and associ-
ation of patient characteristics with risk of hypoglycemiain Japanese patients with T2DM. In the present sub-
analysis, we stratified the ALOHA safety analysis cohort
in insulin-naïve and insulin non-naive sub-groups. The
present results further add to our understanding on inci-




Between 2007 and 2009, this observational, non-
interventional, 24-week follow-up, post-marketing surveil-
lance study recruited 5223 patients from 987 centers across
Japan. The detailed design and methodology of the ALOHA
study is published elsewhere [23,25,26]. In the current
study, Japanese patients having T2DM and inadequate gly-
cemic control, were followed for 24 weeks to determine the
incidence of hypoglycemia and any patient characteristics
which predicted occurrence of hypoglycemia.
This study was endorsed by the Health Authority in
Japan and was conducted as a post-marketing surveillance
in accordance with the Good Post-marketing Study Practice
(GPSP) [27], and Good Vigilance Practice [28] in Japan.
Patients
Patients having T2DM who were to start BOT with in-
sulin glargine, but who were naïve to treatment with in-
sulin glargine, were eligible for participating in the
ALOHA study. The study included patients having
T2DM who satisfied the following criteria within 4 weeks
screening period before initiation of insulin glargine: 1)
received treatment with OADs for ≥12 weeks, 2) had
HbA1c (National Glycohemoglobin Standardization Pro-
gram [NGSP]*) values ≥7.9% and <12.4%, and 3) had
BMI < 30 kg/m2.
*The NGSP values were selected based on the JDS
values (≥7.5% and <12.0%, respectively). HbA1c data
were collected as JDS values and then converted to
NGSP values by the following conversion formula:
HbA1c (NGSP) = 1.02 × HbA1c (JDS) + 0.25% with
rounding off to the first decimal place [29].
Treatment
Initiation of insulin treatment and adjusting insulin
doses were determined by attending physicians. Con-
comitant OADs were also selected by the physicians, as
part of routine clinical care.
Patients who required additional insulin, for example,
bolus insulin, were terminated to follow-up due to no
longer fulfilling the inclusion criteria.
Data collection
All eligible patients’ data were collected via paper-based
case report forms (CRFs). Data collected included back-
ground characteristics (gender, age, duration of diabetes,
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tions, type and dose of prior drug therapy, etc.), treat-
ment details, patient compliance, laboratory tests, and
AEs.Study assessment
Safety and effectiveness data were collected over 24 weeks.
Effectiveness parameters included HbA1c, fasting plasma
glucose (FPG), postprandial glucose (PPG), and weight.
Safety was determined by documenting all AEs and ac-
companying symptoms of hypoglycemia as reported by
the attending physicians during the observational period.
For serious AEs its seriousness, intervention, outcome
and causal relationship to glargine were evaluated. Hypo-
glycemic episodes were counted by physicians’ documen-
tation (any hypoglycemic episodes and any symptoms
derived from hypoglycemia), based on patients’ reports.
Severe hypoglycemia included hypoglycemic episodes sat-
isfying any of the following serious AEs criteria; 1) resulted
in death, 2) life-threatening, 3) required or prolonged
inpatient hospitalization, 4) persistently or significantly
disabling/ incapacitating, 5) a congenital anomaly, and/or
6) medically important.Total centers (N=987) 
Total patients (N=5223) 
CRFs collected 
Total centers (N=978) 


















Insulin-naïve group (N=3732) Insulin n
to insulin
Figure 1 Patient disposition.Statistical analysis
We used Fisher exact test to determine the difference
between patients with or without hypoglycemia, accord-
ing to patient characteristics. After calculating differ-
ences in hypoglycemia incidence and its 95% confidence
intervals (CI) among subgroups, we calculated number
needed to harm (NNH) by the inverse of incidence dif-
ference between subgroups. Among subgroups having
statistically significant differences, we calculated multi-
variate adjusted relative risk estimates and 95% CI by
using negative binomial regression model. All statistical
tests were two-sided at α = 0.05. All statistical calcula-
tions were performed using SAS system software, ver-
sion 9.1.3 (SAS Institute Inc., Cary, NC, USA) and R
2.15.2.
Results
Patient disposition and baseline characteristics
Of 5223 patients enrolled in the study, 5181 patients
completed CRFs. Of these, 4219 patients were included
in the safety analysis set (Figure 1). This set is further di-
vided into 2 sub-groups: 1) Insulin-naïve group: patients
treated with OADs (n = 3732), and 2) Insulin non-naïve
group: patients treated with OADs + insulin other thanCRFs not collected 
Total centers (N=9) 
Total patients (N=42) 
from safety analysis set (N=962) 
ented glargine administration data outside of 
tion period (n=2) 
ate (n=4) 
istered during study (n=32) 
ministered (n=6) 
rmation after administration (n=20) 
ot administered  over 12 weeks (n=67) 
f laboratory data during pre-study 4-wk 
(HbA1c, weight, height) (n=619) 
e HbA1c < 7.9% or ≥ 12.5% (n=112)  
30kg/m2  (n=84) 
f evaluation of overall safety (n=4) 
nsulin (n=73) 
ministered OAD (n=30) 
on-naïve group: Switching from other insulin 
 glargine (N=487) 
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gine (n = 487).
Baseline characteristics of total and sub-group patients
are presented in Table 1. Majority of patients in both
groups had duration of T2DM >5 years. In insulin-naïve
group receiving only OADs, majority of patients were pre-
scribed combination of 2 or 3 OADs, while in insulin non-
naïve group receiving insulin +OADs, patients commonly
received 1 or 2 OADs. There were differences in the types
of OADs used in insulin-naïve group (sulfonylurea [SU] –
88.9%, biguanides [BG] – 47.7%, and alpha-glucosidase in-
hibitors [α-GI] – 46%) and insulin non-naïve group (SU –
55.6%, α-GI – 52.2%, and BG – 42.9%). The prevalence of
diabetic complications was similar in both groups.
The HbA1c value at baseline in the naïve population





Age (years) Missing data
Mean ± SD 62
Weight (kg) Mean ± SD 61
BMI (kg/m2) Mean ± SD 2













Diabetic complications Neuropathy 10
Retinopathy 11
Nephropathy 11





*Insulin-naïve group: patients having been treated with OADs (n = 3732).
†Insulin non-naïve group: patients treated with OADs + insulin other than insulin gla
Abbreviations: α-GI alpha-glucosidase inhibitors, BG biguanide, BMI body mass index
SD standard deviation, SU sulfonylurea, TZD, thiazolidinedione.the baseline HbA1c value was 9.08 ± 1.11% (n = 487).
The HbA1c values at the end of the study were 8.07 ±
1.21% (n = 3337) and 8.46 ± 1.39% (n = 424) in the naïve
and non-naïve populations, respectively.
Hypoglycemia
The data on incidence of hypoglycemia in total as well as
subgroup patients have been presented in Table 2. In total
patients, incidence of hypoglycemia was 1.0% (0.035
episodes/patient-years). Incidence of hypoglycemia in
insulin-naïve group (1.1% [0.036 episodes/patient-years])
and insulin non-naïve group (0.6% [0.029 episodes/pati-
ent-years]) was similar to the overall incidence. The differ-
ence in the incidence of hypoglycemia between naïve and
non-naïve groups was not statistically significant; p-value
was 0.4752 by fisher exact test. Among total 4219 patients,ts
Total Insulin-naïve group* Insulin non-naïve group†
4219 3732 487
1 1 0
85 (58.9) 2237 (59.9) 248 (50.9)
8 8 0
.8 ± 12.1 62.6 ± 12.1 64.0 ± 12.1
.7 ± 11.6 61.8 ± 11.7 61.0 ± 11.5
3.8 ± 3.3 23.7 ± 3.3 24.0 ± 3.3
41 (5.7) 221 (5.9) 20 (4.1)
0 (1.2) 46 (1.2) 4 0.8)
6 (11.0) 436 (11.7) 30 (6.2)
62 (82.1) 3029 (81.2) 433 (88.9)
5 (23.1) 757 (20.3) 218 (44.8)
19 (40.7) 1537 (41.2) 182 (37.4)
89 (28.2) 1114 (29.8) 75 (15.4)
36 (8.0) 324 (8.7) 12 (2.5)
91 (47.2) 1782 (47.7) 209 (42.9)
87 (85.0) 3316 (88.9) 271 (55.6)
12 (7.4) 269 (7.2) 43 (8.8)
71 (46.7) 1717 (46.0) 254 (52.2)
60 (32.2) 1287 (34.5) 73 (15.0)
83 (25.7) 933 (25.0) 150 (30.8)
48 (27.2) 971 (26.0) 177 (36.3)
21 (26.6) 953 (25.5) 168 (34.5)
7 (23.6) 892 (23.9) 105 (21.6)
30 (24.4) 933 (25.0) 97 (19.9)
58 (36.9) 1375 (36.8) 183 (37.6)
4 (15.0) 532 (14.3) 102 (20.9)
rgine, and switching to OADs + insulin glargine (n = 487).
, eGFR estimated glomerular filtration rate, OADs oral antidiabetic drugs,
Table 2 Cumulative incidence and rate of hypoglycemia in overall and sub-group patients
Parameters Total Insulin-naïve group* Insulin non-naïve group†
N 4219 3732 487
Patients with hypoglycemia, n (%) 44 (1.0) 41 (1.1) 3 (0.6)
Patient-years 1801.2 1596.7 204.5
Episodes, n 63 57 6
Incidence rate (episodes/patient-year) 0.035 0.036 0.029
Note:
*Insulin-naïve group: patients having been treated with OADs (n = 3732).
†Insulin-naïve group: patients treated with OADs + insulin other than insulin glargine, and switching to OADs + insulin glargine (n = 487).
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patient-years). At the end of the 24-weeks study period, cu-
mulative incidence of hypoglycemia was 1.0% (Figure 2a),
and cumulative incidence rate of hypoglycemia was 0.016
episodes/patient (Figure 2b).
Altogether, 44 patients reported 63 hypoglycemic epi-
sodes: 37 (0.88%) patients had 1 episode, 3 (0.07%) had 2
episodes, 2 (0.05%) had 4 episodes, and 1 (0.02%) patient
each had 5 and 7 episodes. The details of the 63 hypo-
glycemic episodes were as follows: 20 episodes with con-
vincing symptoms, 31 episodes in patients with morningFigure 2 a) Cumulative incidence and b) cumulative incidence
rate (episodes/patient) of hypoglycemia.injection, 24 episodes in patients with bedtime injection, 4
episodes identified by self-monitored blood glucose meas-
urement (2 patients), and 2 episodes in the night (1 in
evening and 1 with bedtime injection).
Hypoglycemia incidence and rate according to patient
characteristics in insulin-naïve group: univariate analysis
When we assessed incidence of hypoglycemia and its rate
with various patient characteristics in insulin-naïve patients,
there was no statistically significant difference in sub-
groups such as sex, BMI, duration of diabetes, renal dis-
order not due to diabetes, baseline HbA1c, FPG, OADs
prescribed prior to and during study, and compliance to
diet and exercise (data not shown). There was a statistically
significant difference in hypoglycemic incidence in insulin-
naïve patients in subgroups according to age, diabetic com-
plications, estimated glomerular filtration rate (eGFR), and
PPG levels (Table 3). Among the diabetic complications,
the NNH was low for retinopathy and/or nephropathy.
Also, for eGFR <60 mL/min/1.73 m2, the NNH was lower
than eGFR levels of >60 mL/min/1.73 m2.
Since, there were only 6 episodes of hypoglycemia in 3
patients in insulin non-naïve group, we did not assess
them in the univariate analysis.
Predictors of hypoglycemia in insulin-naïve group: multi-
variate analysis
All factors having a statistically significant difference in
the univariate analysis (Table 3), were examined by multi-
variate analysis. PPG was excluded because of missing
data. Due to a very few hypoglycemic episodes, diabetic
complication category was forced to be contracted into
dichotomous unlike all combinations of complications
presented in Table 3. Multivariate adjusted negative bino-
mial regression model revealed that among the parameters
studied, poor renal function defined as eGFR <60 mL/
min/1.73 m2 was the only statistically significant risk fac-
tor of hypoglycemic events (relative risk [RR] 5.34, 95%
confidence interval [CI] 1.48-22.85, P <0.05).
Discussion
This observational, non-interventional, 24-week post-
marketing surveillance study in Japan provides detailed
Table 3 Cumulative incidence and rate of hypoglycemia in insulin-naïve group (N = 3732), according to patient characteristics
Characteristics Total patients, N Patients havinghypoglycemia, n (%) P value
Number needed
to harm (95% CI) Patient-years Episodes, n
Incidence rate
(episodes/patient-year)
Age (years) <65 2046 14 (0.7) < 0.05 Reference 880.5 21 0.024
≥65 1678 27 (1.6) 108 (62–445) 714.2 36 0.050
Diabetic complications No microvascular complication 1889 18 (1.0) < 0.05 Reference 811.1 24 0.030
Neuropathy only 297 6 (2.0) 94 (n.s.) 127.9 6 0.047
Retinopathy only 318 1 (0.3) -* 138.3 1 0.007
Nephropathy only 356 2 (0.6) -* 152.5 5 0.033
Neuropathy + Retinopathy 174 1 (0.6) -* 74.9 1 0.013
Neuropathy + Nephropathy 142 0 (0.0) -* 59.5 0 0.000
Retinopathy + Nephropathy 154 5 (3.2) 44 (n.s.) 64.1 7 0.109
Neuropathy + Retinopathy + Nephropathy 301 5 (1.7) 141 (n.s.) 126.4 6 0.047
eGFR (mL/min/1.73 m2) 90≤ 933 3 (0.3) < 0.01 Reference 400.6 4 0.010
60≤, <90 1375 12 (0.9) 181 (n.s.) 589.0 13 0.022
<60 532 11 (2.1) 57 (33–207) 225.0 16 0.071
Unknown 892 15 (1.7) 74 (44–227) 382.1 24 0.063
PPG (mg/dL) <140 45 1 (2.2) < 0.01 57 (n.s.) 19.1 1 0.052
140≤, <180 132 5 (3.8) 30 (15–4008) 57.2 8 0.140
180≤, <220 235 3 (1.3) 125 (n.s.) 103.5 7 0.068
≥220 1043 5 (0.5) Reference 446.7 13 0.029
Note: Since the incidence of hypoglycemia was very low in insulin non-naïve group patients (3 patients having 6 episodes of hypoglycemia), we have not
reported the univariate analysis of that data.
Insulin-naïve group: patients having been treated with OADs (n = 3732).
Insulin non-naïve group: patients treated with OADs + insulin other than insulin glargine, and switching to OADs + insulin glargine (n = 487).
Each of the subgroups were compared to ‘Reference’ subgroup by all characteristics.
Abbreviations: CI confidence interval, eGFR estimated glomerular filtration rate, PPG post-prandial glucose, n.s not significant.
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T2DM patients using BOT with insulin glargine. The over-
all incidence of hypoglycemia was 1.0%, with majority of
patients experienced hypoglycemia only once during 24-
week follow-up period. The study also demonstrated, for
the first time, that among insulin-naïve T2DM Japanese
patients, hypoglycemia is associated with poor renal
function.
The prospective, observational registry in Germany
demonstrated that hypoglycemia is a frequent AE in
insulin-naïve T2DM patients having insufficient glycemic
control on OADs, and receiving intensified antidiabetic
treatment [30]. The rate of hypoglycemia in this study,
over a 12-month follow-up period, was mild: 13.0%,
moderate: 0.7%, and severe: 0.5%. The results of this
study indicated that the risk of hypoglycemia might be
substantially reduced by carefully selecting antidiabetic
pharmacotherapy [31]. Earlier randomized trials using
BOT with insulin glargine reported high incidence of
hypoglycemia. In the HOE 901/3002 study, 33% of
insulin-naïve patients receiving insulin glargine experi-
enced at least one episode of symptomatic hypoglycemia,
and 9.9% patients experienced nocturnal hypoglycemia
[12]. In the HOE 901/2004 study, among T2DM patients
having inadequate glycemic control on OADs, 22.1% and
7.3% of patients receiving insulin glargine experienced
symptomatic hypoglycemia and nocturnal hypoglycemia,
respectively [13]. Other studies reported the hypoglycemia
incidence rate in the range of 0.7 to 5.2 episodes per
patient-year [14,16,17,32]. Outside the clinical setting,
an earlier observational study reported 0.1% prevalence
of hypoglycemia [33]. In the current study, rate of
hypoglycemia in insulin-naïve patients was 1.1%, which is
higher than that reported in the earlier observational
study. The difference in the rate of hypoglycemia can be
due to heterogeneity of the study populations and different
definitions of hypoglycemia used in these studies. The
higher hypoglycemia rate in clinical trials could be due to
intensive antidiabetic treatments used to achieve glycemic
targets, as opposed to the observational studies.
The American Diabetes Association/European Association
for the Study of Diabetes (ADA/EASD) guidelines [34]
and the Japan Diabetes Society (JDS) treatment guide [35]
recommend intervention at the time of diagnosis, with
OADs in combination with lifestyle changes in diet and
exercise. In patients who do not meet glycemic goals by
taking only OADs, the guidelines recommend timely
augmentation of this therapy with additional agents and
early addition of insulin therapy. However, there exist
patient barriers such as fear of hypoglycemia, injections
and weight gain, as well as physicians’ concerns such as
reluctance to prescribe insulin, result in non-adherence to
initiation and intensification of insulin treatment, leading
to delayed use of effective therapy [36,37]. Early initiationof insulin therapy might help patients with T2DM achieve
long-term glycemic control and improve quality of life. It
has been demonstrated that first insulinization with basal
insulin is effective and safe with reduced AEs including
hypoglycemia, in clinical trial [38], as well as real-world
setting [15]. However, in the current study, majority of
patients had T2DM for more than 5 years and still were
prescribed only one and/or two OADs (61.5%) and were
insulin-naïve (81%). Thus, physician and patient education
is necessary to overcome barriers to insulin use and
ensure its appropriate and optimal use.
In the present study, we demonstrated association of
hypoglycemia with older age (relative risk [RR] 1.58, 95%
CI: 0.74, 3.44). Advanced age has been a contributing fac-
tor to severe hypoglycemia in previous population-based
studies [39,40]. Earlier ACCORD [41] and ADVANCE [9]
trials reported significant associations between older age
and risk of severe hypoglycemia. In an earlier study in
insulin-naïve T2DM patients, age <65 years was an inde-
pendent predictor of reduced incidence of hypoglycemia
(OR 0.76; 95% CI 0.59-0.96) [31]. The DAWN Japan study
demonstrated that old age was one of the top three con-
cerns for physicians to delay insulin initiation [42]. Hence,
future studies to address appropriate strategies to over-
come these physician barriers are warranted.
In ADVANCE study, history of microvascular disease
was associated with twofold increase in risk of severe
hypoglycemia (hazards ratio 2.1, 95% CI 1.5 to 3.) [9]. Dia-
betic complications such as coronary artery disease and
peripheral neuropathy are also known as risk factors for
hypoglycemia [22,43]. In line with the earlier evidence, in
the current study also, hypoglycemia was associated with
presence of diabetic complication (s) (RR 1.36, 95% CI:
0.66, 2.83). Many earlier studies reported poor renal func-
tion diagnosed by low eGFR as a significant predictor of
first of recurrent hypoglycemia [22,43]. Our results confirm
this by showing significant association of hypoglycemia
and poor renal function i.e. eGFR <60 mL/min/1.73 m2
(RR 5.34, 95% CI: 1.48, 22.85). However, the risk difference
was very low and not clinically relevant.
One of the inclusion criteria of the current study is
BMI <30 kg/m2. Accordingly, the mean BMI of the pa-
tients in safety analysis set was 23.8 kg/m2. Earlier stud-
ies demonstrated that low BMI was an independent risk
factor of severe hypoglycemia [9,41]. However, these
studies recruited global population of T2DM patients. In
the current study, the incidence of severe hypoglycemia
was 0.1%. This can be due to the lower cut-off levels of
BMI for overweight and obesity in Asian population as
compared to the Western population [44].
The results of the present observational study explore
the incidence and predictors of hypoglycemia in real-life
clinical practice in insulin-naïve diabetic patients in
Japan having inadequate glycemic control and who are
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population might not represent general T2DM patient
population who initiate insulin glargine. Also, unlike a
treat-to-target trial, the present observational study has
no interventional target of glycemic control. Another
limitation of the study is that because of the observa-
tional nature of the study, it is likely that incidence of
hypoglycemia might have been under-reported. The data
on hypoglycemia in patients receiving insulin other than
glargine and switching to insulin glargine will be further
elaborated in subsequent publication, which would in-
clude comprehensive results of effectiveness and safety
in this cohort.
Conclusions
In conclusion, our results suggest that BOT using insulin
glargine is an option of insulin therapy with a 1% risk of
hypoglycemia in insulin-naïve patients with T2DM with
inadequate glycemic control. Age, presence of diabetic
complications, and poor renal function were the predic-
tors of hypoglycemia in insulin-naïve patients. Patients
with low renal function might need a careful follow-up.
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